{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:18:24Z","timestamp":1792189104392,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To examine the association between the 2014 U.S. Food and Drug Administration (FDA) safety communication on power morcellation and surgical approach and morbidity after myomectomy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>In this retrospective cohort study, data were abstracted from the American College of Surgeons National Surgical Quality Improvement Program database on 3,160 myomectomies between April 2012 and December 2013 (pre-FDA) and 4,378 between April 2014 and December 2015 (post-FDA). Aims were to 1) compare rates of abdominal and laparoscopic myomectomy pre-FDA and post-FDA (primary outcome), 2) directly compare the morbidity of abdominal and laparoscopic myomectomy during each time period (secondary outcome 1), and 3) compare the morbidity after all myomectomies performed pre-FDA and post-FDA (secondary outcome 2). Adjusted means, odds ratios, and rate ratios with 95% confidence intervals were calculated using linear, logistic, and Poisson regression, respectively, adjusting for age, race, ethnicity, body mass index, and myoma burden.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Myomectomies performed post-FDA were more likely to be abdominal (60.0%, 95% confidence interval [CI] 58.6\u201361.5%) than laparoscopic (40.0%, 95% CI 38.5\u201341.4%) as compared with myomectomies pre-FDA, which were equally divided between surgical approaches (49.1% abdominal, 95% CI 47.4\u201350.9% compared with 50.9% laparoscopic, 95% CI 49.1\u201352.6%; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001). When directly compared with laparoscopic myomectomy, abdominal myomectomy was associated with longer hospitalizations, higher readmission rates, and greater morbidity both pre-FDA and post-FDA (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.05, all comparisons). Adjusted models demonstrated shorter operative times post-FDA for all myomectomies (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001), although composite morbidity was similar between myomectomies performed pre-FDA and post-FDA (<jats:italic toggle=\"yes\">P<\/jats:italic>=.809).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>The FDA safety communication on power morcellation was associated with an 11% absolute increase in the use of abdominal myomectomy. Although morbidity is consistently higher after abdominal as compared with laparoscopic myomectomy, the increased reliance on abdominal myomectomy post-FDA did not result in clinically significant changes in morbidity in this cohort.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000002035","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T14:47:36Z","timestamp":1494341256000},"page":"1007-1013","source":"Crossref","is-referenced-by-count":57,"title":["Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation"],"prefix":"10.1097","volume":"129","author":[{"given":"Natalie C.","family":"Stentz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura G.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejogrb.2009.03.009","article-title":"Laparoscopic versus open myomectomy\u2014a meta-analysis of randomized controlled trials","volume":"145","author":"Jin","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R2-20230711","article-title":"Doctors eye cancer risk in uterine procedure","author":"Levitz","year":"December 18, 2013","journal-title":"Wall Street J"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"98.e1","DOI":"10.1016\/j.ajog.2015.08.047","article-title":"Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation","volume":"214","author":"Harris","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jamcollsurg.2008.07.018","article-title":"Blueprint for a new American College of Surgeons: National Surgical Quality Improvement Program","volume":"207","author":"Birkmeyer","year":"2008","journal-title":"J Am Coll Surg"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.yasu.2010.05.003","article-title":"Quality improvement in surgery: the American College of Surgeons National Surgical Quality Improvement Program approach","volume":"44","author":"Ingraham","year":"2010","journal-title":"Adv Surg"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/SLA.0b013e3181823485","article-title":"Successful implementation of the Department of Veterans Affairs' National Surgical Quality Improvement Program in the private sector: the Patient Safety in Surgery study","volume":"248","author":"Khuri","year":"2008","journal-title":"Ann Surg"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jamcollsurg.2009.09.031","article-title":"Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program","volume":"210","author":"Shiloach","year":"2010","journal-title":"J Am Coll Surg"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.maturitas.2008.09.005","article-title":"The normal menopause transition","volume":"61","author":"McKinlay","year":"2008","journal-title":"Maturitas"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0015-0282(97)81482-3","article-title":"Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors","volume":"68","author":"van Noord","year":"1997","journal-title":"Fertil Steril"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/AOG.0000000000001111","article-title":"Association of the U.S. Food and Drug Administration morcellation warning with rates of minimally invasive hysterectomy and myomectomy","volume":"126","author":"Barron","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gmit.2014.02.001","article-title":"Laparoscopic myomectomy\u2014the gold standard","volume":"3","author":"Herrmann","year":"2014","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0002-9378(96)70445-3","article-title":"Laparoscopic versus abdominal myomectomy: a prospective, randomized trial to evaluate benefits in early outcome","volume":"174","author":"Mais","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jmig.2012.12.010","article-title":"Robotic-assisted laparoscopic vs abdominal and laparoscopic myomectomy: systematic review and meta-analysis","volume":"20","author":"Pundri","year":"2013","journal-title":"J Minim Invasive Gynecol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10397-015-0894-4","article-title":"The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis","volume":"12","author":"Pritts","year":"2015","journal-title":"Gynecol Surg"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2014.206","article-title":"Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy","volume":"1","author":"Wright","year":"2015","journal-title":"JAMA Oncol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/1471-0528.14265","article-title":"Disseminated leiomyoma cells can be identified following conventional myomectomy","volume":"123","author":"Sandberg","year":"2016","journal-title":"BJOG"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201706000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T18:19:15Z","timestamp":1689099555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201706000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002035","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}